Short answer
Tesamorelin is a stabilised 44 amino acid GHRH analogue with a metabolic literature centred on visceral adipose measures. CJC-1295 without DAC is a shortened GRF 1 to 29 analogue with a short described half life, most often studied alongside Ipamorelin. Both are supplied as lyophilised research vials.
Both compounds act at the growth hormone releasing hormone receptor, which is why they are so often confused. The differences sit in the sequence length, the stabilisation strategy and the literature each one carries.
What is each compound?
Tesamorelin is a synthetic 44 amino acid GHRH analogue stabilised at the N terminus, studied in growth hormone axis and visceral adipose models.
CJC-1295 without DAC is a modified GRF 1 to 29 fragment, the shortest sequence that retains GHRH receptor activity, with substitutions that slow enzymatic breakdown.
| Property | Tesamorelin | CJC-1295 no DAC |
|---|---|---|
| Peptide class | Stabilised full length GHRH analogue | Modified GRF 1 to 29 fragment |
| Sequence length | 44 amino acids | 29 amino acids |
| Receptor studied | GHRH receptor | GHRH receptor |
| Described half life | Extended against native GHRH | Short |
| Main research focus | GH axis and visceral adipose measures | GH release, often blended with Ipamorelin |
| Formats supplied | 5mg and 10mg lyophilised vial | 10mg vial, and a 10mg blend vial |
How do the research literatures differ?
Tesamorelin appears mainly in metabolic literature, where the measures of interest are visceral adipose tissue, lipid parameters and the GH and IGF-1 axis.
CJC-1295 appears mainly in growth hormone release characterisation and in comparative work with ghrelin receptor secretagogues such as Ipamorelin, which act through a separate receptor.
How do they compare in laboratory handling?
- Both arrive as lyophilised powder and are reconstituted in the laboratory.
- Both are stored unopened at -20°C and refrigerated once prepared.
- Vial mass differs, so concentration must be recalculated per vial rather than reused.
- Neither carries a marketing authorisation in the European Union.
Which one fits which research question?
If the question is about the GH axis alongside adipose or lipid measures, the Tesamorelin literature is the deeper one. If the question is about GHRH receptor mediated release itself, or about pairing a GHRH analogue with a ghrelin receptor secretagogue, CJC-1295 carries more comparative work.
What neither comparison establishes
Nothing here ranks the compounds for any use in humans. Both are research compounds, and the published record describes mechanism and measurement, not outcomes outside the study setting.
Research use only
Both compounds supplied by Vitality Peps are for in vitro laboratory research only. Not medicines, not supplements, not for human or veterinary consumption. Nothing above is dosing guidance.
Frequently asked questions
What do Tesamorelin and CJC-1295 have in common?
Both are synthetic analogues of growth hormone releasing hormone and both are studied at the GHRH receptor rather than the ghrelin receptor.
What is the main structural difference?
Tesamorelin is a full length 44 residue analogue with an N terminal trans 3 hexenoyl group. CJC-1295 without DAC is based on the shortened GRF 1 to 29 fragment with four amino acid substitutions.
Which one has the longer described half life?
CJC-1295 with a drug affinity complex is described as long acting. The no DAC version stocked here is described as short acting, closer to Tesamorelin in that respect.
Which is studied with Ipamorelin?
CJC-1295 without DAC, which is why a prepared blend vial exists. Tesamorelin literature is largely standalone and metabolic.
For research purposes only. Not for human consumption. This article is educational and references published laboratory research; it is not medical advice and does not describe an approved use of any compound.